Affordable Access

deepdyve-link
Publisher Website

Intraoral versus extraoral photobiomodulation therapy in the prevention of oral mucositis in HSCT patients: a randomized, single-blind, controlled clinical trial.

Authors
  • Ramos-Pinto, Mariana Bitu1
  • de Lima Gusmão, Teresa Paula1
  • Schmidt-Filho, Jayr2
  • Jaguar, Graziella Chagas1
  • Martins, Manoela Domingues3
  • Alves, Fábio Abreu4, 5, 6
  • 1 Stomatology Department, A.C. Camargo Cancer Center, Sao Paulo, Brazil. , (Brazil)
  • 2 Hematology Department, A.C. Camargo Cancer Center, Sao Paulo, Brazil. , (Brazil)
  • 3 Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. , (Brazil)
  • 4 Stomatology Department, A.C. Camargo Cancer Center, Sao Paulo, Brazil. [email protected] , (Brazil)
  • 5 Stomatology Department, School of Dentistry, Sao Paulo University, Sao Paulo, Brazil. [email protected] , (Brazil)
  • 6 Departamento de Estomatologia, AC Camargo Cancer Center, R: Prof. Antônio Prudente, 211, Bairro: Liberdade, São Paulo, SP, CEP: 01509-900, Brazil. [email protected] , (Brazil)
Type
Published Article
Journal
Supportive Care in Cancer
Publisher
Springer-Verlag
Publication Date
Nov 01, 2021
Volume
29
Issue
11
Pages
6495–6503
Identifiers
DOI: 10.1007/s00520-021-06228-3
PMID: 33905011
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To compare the efficacy of intraoral and extraoral photobiomodulation (PBM) protocols for the prevention of oral mucositis (OM) in hematopoietic stem cell transplantation (HSCT) patients. A total of 60 patients was randomized into intraoral PBM (IOPBM) and extraoral PBM (EOPBM) groups. Both PBM protocols were well tolerated and no side effects were observed. EOPBM session times were one fourth of IOPBM durations. Of 60 patients, 35 (58.3%) developed ulcerated OM between day +3 and day +12. No intergroup difference was observed in OM healing times (p = 0.424). The lateral border of the tongue was the most common site affected in both groups. However, the incidence of mucositis on buccal mucosa was significantly reduced in the EOPBM group (p = 0.021). Young patients (OR.5.35, 95%CI 0.94-30.4, p = 0.058) and those who had received myeloablative conditioning (OR.55.1, 95%CI 2.69-1129.3, p = 0.009) were more likely to develop ulcerated OM, whereas autologous HSCT recipients (OR 0.079, 95% CI 0.009-0.67, p = 0.021) had a lower probability of developing ulcerated OM independent of PBM protocol. EOPBM protocol was as effective as IOPBM in the management of OM in HSCT patients, with the advantage of shorter treatment sessions. Trial registration number: RBR-7nww56. Date of trial registration submission: 30th September 2019. © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Report this publication

Statistics

Seen <100 times